Browse the evidence

The metabolic changes induced by GLP-1 agonists can impact adipose and muscle tissue, leading to changes in facial contour and overall appearance.

Understanding these metabolic changes can help practitioners manage patient expectations regarding facial aesthetics.

Tirzepatide reduced the risk of incident major adverse cardiovascular events (MACEs) compared with liraglutide (hazard ratio, 0.58; 95% confidence interval, 0.51–0.66) and semaglutide (0.86; 0.74–0.99).

Practitioners may consider tirzepatide as a more effective option for reducing cardiovascular risks in patients with OSA and T2D.

Tirzepatide was more efficacious in younger, male patients of White ethnicity.

Treatment strategies may need to be tailored based on demographic factors for optimal outcomes.

Tirzepatide reduced incident obstructive sleep apnea (OSA) compared with liraglutide (0.89; 0.82–0.97) but not semaglutide (0.94; 0.86–1.02).

Tirzepatide may be beneficial in managing both diabetes and associated sleep apnea in patients.

GLP-1 agonists had a good safety profile with most adverse effects being mild.

GLP-1 agonists can be considered a safe option for weight management in obese IBD patients.

Incretin-based therapies were associated with a mean reduction in the apnea-hypopnea index (AHI) of -14.45 events/h.

Incretin-based therapies may effectively reduce AHI in OSA patients, improving sleep quality.

Incretin-based therapies showed a greater effect on AHI compared to usual care, with a mean difference of -11.61 events/h.

Incretin-based therapies may be more effective than usual care for improving AHI in OSA patients.

Tirzepatide, a GLP-1/GIP receptor co-agonist, is approved for type 2 diabetes and shows significant reductions in glycemia and body weight compared to GLP-1R mono-agonism with semaglutide.

Tirzepatide may be a more effective treatment option for managing blood sugar and weight in patients with type 2 diabetes.

All 3 eligible maintenance doses of tirzepatide (5, 10, and 15 mg once a week) were effective in increasing total cholesterol (TC), HDL-C, VLDL-C, triglyceride (TG), and waist circumference (WC) changes from baseline compared with control agents.

Tirzepatide may be considered as an effective treatment option for improving lipid profiles and waist circumference in patients with type 2 diabetes.

Only 5 mg once-weekly tirzepatide could induce significant alteration in LDL-C before sensitivity analysis.

Clinicians should note that the 5 mg dose of tirzepatide may be more effective for lowering LDL-C compared to higher doses.

Tirzepatide had superiority over placebo or other antidiabetic agents in controlling lipid and waist circumference levels.

Tirzepatide may be a preferred treatment option for improving lipid profiles and waist circumference in patients with type 2 diabetes.

Four positive signals were found at the system organ classes level for tirzepatide.

Monitoring for specific adverse events is crucial for patients on tirzepatide.

Two patients achieved significant weight loss of 16% and 12.6% in under 9 months using semaglutide.

Clinicians can expect significant weight loss outcomes in similar patients using semaglutide.

Individuals with obesity are at greater risk for developing metabolic diseases such as type 2 diabetes, metabolic dysfunction-associated steatohepatitis, and cardiovascular diseases.

Healthcare providers should monitor metabolic health in patients with obesity.

GLP-1RA use in MUHO is associated with a lower risk of ischemic stroke (HR 0.921) compared to non-use.

GLP-1RAs may be beneficial for reducing ischemic stroke risk in MUHO patients.

Patients with metabolically healthy obesity (MHO) have a markedly lower risk of clinical events compared to those with metabolically unhealthy obesity (MUHO).

Understanding the risk differences can guide treatment decisions for obesity management.

Most ultraprocessed foods overlap with foods high in saturated fat, added sugars, and sodium.

Practitioners should consider the nutritional content of UPFs when advising clients.

The deuterated water method allows for the assessment of muscle tissue protein synthesis rates under free-living conditions.

This method can be used to measure protein synthesis in everyday life, enhancing research relevance.

The use of anti-obesity medications in patients with heart failure may improve functional status, biomarkers of inflammation, and heart failure stability.

Anti-obesity medications may not only aid in weight loss but also enhance overall heart failure management.

Lifestyle modification alone is often insufficient to achieve clinically meaningful weight loss.

Clinicians should consider pharmacotherapy in conjunction with lifestyle changes for effective weight management.

Tirzepatide was recently approved by the FDA for the management of type 2 diabetes.

Tirzepatide can be utilized in clinical settings for managing type 2 diabetes, with potential implications for weight loss.

Metabolic and bariatric surgery is independently associated with a lower risk of incident cancer than nonsurgical obesity care.

Practitioners should consider metabolic and bariatric surgery as a viable option for reducing cancer risk in obese patients.

Semaglutide has a favorable safety profile across diverse patient populations and treatment durations.

Clinicians can consider semaglutide as a safe option for managing type 2 diabetes and obesity.

No significant differences in adverse events were observed between semaglutide and comparator groups.

This suggests that semaglutide is as safe as other treatments in terms of adverse events.